Murray Stewart
CIK 1723450 · Interim Chief Medical Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$32.8K
Companies
5
Total Filings
19
Lifetime Open-Market Net
-$137.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $4.65 | — | $0 | 2 | 2026-06-12 |
| XFOR | Interim Chief Medical Officer | 7,883 | $4.16 | $32.8K | -$137.9K | 9 | 2026-01-05 |
| AMRN | Director | — | $14.38 | — | $0 | 1 | 2023-01-12 |
| RYTM | Chief Medical Officer | — | $115.73 | — | $0 | 5 | 2021-02-16 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Executive Vice President, R&D | 50,000 | — | — | $0 | 2 | 2018-02-14 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-10-21 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2020-07-02 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2020-02-19 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2019-04-02 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2019-02-15 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2018-10-17 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2018-02-14 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-11-29 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.